S. Ozakbas Et Al. , "Does the reason for the switch to fingolimod affect the treatment response?," MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL, pp.585, 2021
Ozakbas, S. Et Al. 2021. Does the reason for the switch to fingolimod affect the treatment response?. MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL , 585.
Ozakbas, S., Aslan, T., Ozdogar, A. T., Abasiyanik, Z., & Sagici, O., (2021). Does the reason for the switch to fingolimod affect the treatment response?. MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL, 585.
Ozakbas, SERKAN Et Al. "Does the reason for the switch to fingolimod affect the treatment response?," MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL, 585, 2021
Ozakbas, SERKAN Et Al. "Does the reason for the switch to fingolimod affect the treatment response?." MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL, pp.585, 2021
Ozakbas, S. Et Al. (2021) . "Does the reason for the switch to fingolimod affect the treatment response?." MULTIPLE SCLEROSIS JOURNAL , vol.27, no.2_SUPPL, p.585.
@article{article, author={SERKAN ÖZAKBAŞ Et Al. }, title={Does the reason for the switch to fingolimod affect the treatment response?}, journal={MULTIPLE SCLEROSIS JOURNAL}, year=2021, pages={585} }